| SC 13G/A | 2024-02-13 | VANGUARD GROUP INC | Akebia Therapeutics, Inc. | 7,607,472 | 4.0% | EDGAR |
| SC 13G/A | 2024-02-09 | Satter Muneer A | Akebia Therapeutics, Inc. | 16,205,119 | 8.6% | EDGAR |
| SC 13G/A | 2023-02-10 | Satter Muneer A | Akebia Therapeutics, Inc. | 15,090,119 | 8.2% | EDGAR |
| SC 13G/A | 2023-02-09 | VANGUARD GROUP INC | Akebia Therapeutics, Inc. | 11,238,870 | 6.1% | EDGAR |
| SC 13G/A | 2023-01-20 | STATE STREET CORP | Akebia Therapeutics, Inc. | - | 0.3% | EDGAR |
| SC 13G | 2022-12-19 | Satter Muneer A | Akebia Therapeutics, Inc. | 13,864,330 | 7.5% | EDGAR |
| SC 13G | 2022-07-08 | BlackRock Inc. | Akebia Therapeutics, Inc. | 4,340,026 | 2.4% | EDGAR |
| SC 13G/A | 2022-06-09 | VANGUARD GROUP INC | Akebia Therapeutics, Inc. | 18,359,420 | 10.0% | EDGAR |
| SC 13G/A | 2022-02-10 | STATE STREET CORP | Akebia Therapeutics, Inc. | - | 6.7% | EDGAR |
| SC 13G/A | 2022-02-09 | VANGUARD GROUP INC | Akebia Therapeutics, Inc. | 13,235,669 | 7.6% | EDGAR |
| SC 13G/A | 2022-02-07 | BlackRock Inc. | Akebia Therapeutics, Inc. | 14,124,215 | 8.1% | EDGAR |
| SC 13G/A | 2021-08-10 | WELLINGTON MANAGEMENT GROUP LLP | Akebia Therapeutics, Inc. | 711 | 0.0% | EDGAR |
| SC 13G/A | 2021-07-12 | STATE STREET CORP | Akebia Therapeutics, Inc. | - | 8.8% | EDGAR |
| SC 13G/A | 2021-02-12 | Nantahala Capital Management, LLC | Akebia Therapeutics, Inc. | 7,040,487 | 4.9% | EDGAR |
| SC 13G | 2021-02-11 | STATE STREET CORP | Akebia Therapeutics, Inc. | - | 15.6% | EDGAR |
| SC 13G/A | 2021-02-10 | STATE STREET CORP | Akebia Therapeutics, Inc. | - | 15.8% | EDGAR |
| SC 13G | 2021-02-10 | VANGUARD GROUP INC | Akebia Therapeutics, Inc. | 8,434,759 | 5.8% | EDGAR |
| SC 13G/A | 2021-02-03 | WELLINGTON MANAGEMENT GROUP LLP | Akebia Therapeutics, Inc. | 12,590,463 | 8.7% | EDGAR |
| SC 13G/A | 2021-01-29 | BlackRock Inc. | Akebia Therapeutics, Inc. | 11,397,548 | 7.9% | EDGAR |
| SC 13G | 2020-11-10 | WELLINGTON MANAGEMENT GROUP LLP | Akebia Therapeutics, Inc. | 17,698,113 | 12.4% | EDGAR |